Oligonucleotides for Cardiovascular and Metabolic Disease Summit

Developed from research with industry leaders, including AstraZeneca, Ionis, and Amgen, this intimate digital conference will pre-competitively advance ASO, RNAi, and RNA therapeutics beyond the liver, by comprehensively analyzing pioneering research and the latest data specific to cardiovascular and cardiometabolic disease in both rare and chronic settings. Hear world-class insights from bench to bedside and troubleshoot clinical challenges with other stakeholders, including maximizing on-target delivery, achieving appropriate dosage and administration, and optimizing clinical trial design to accelerate the development of life-changing therapies for millions of patients worldwide. Join over 40 other oligonucleotide and cardiometabolic drug developers at this uniquely concentrated conference dedicated to advancing the next generation of oligonucleotide therapeutics for cardiometabolic disease.

Others Details

URL: Brochure: https://go.evvnt.com/660158-3?pid=6581 Speakers: Dan Swerdlow, Senior Medical Director, Silence Therapeutics, David Blakey, Chief Scientific Officer, MiNA Therapeutics, Elena Feinstein, Chief Scientific Officer, Quark Pharmaceuticals, Marcus Schindler, Senior Vice President, Head of Global Drug Discovery, Novo Nordisk, Marie Wikstrom, Lindholm Vice President, Head of Molecular Design, Silence Therapeutics and more. Time: 07:00 - 16:30